Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pierre Fabre
Fierce Pharma
FDA to reconsider rejected cell therapy. Could uniQure be next?
As the FDA walks back its previous criticism of Ebvallo's single-arm trial, there's hope for a reversal for uniQure's gene therapy, too.
Angus Liu
May 7, 2026 10:40am
Scorpion bags $553M deal for preclinical lung cancer assets
Apr 4, 2023 8:00am
Forte taps new exec amid shareholder dissent—Chutes & Ladders
Jun 10, 2022 9:30am
Pierre Fabre and Roche extend pact on companion diagnostic for cancer
May 18, 2018 9:14am
Pierre Fabre forms connected underwear collaboration
May 14, 2018 8:40am
Pierre Fabre buys up Igenica preclinical I-O meds
May 24, 2017 5:52am
